Fully Licensed Colombian EU Export Cultivation & Processing Hub

PRINTED ON: *November 15, 2026, 10:25 AM (EST)* **PUBLISHED ON:** *May 21, 2026, 3:00 AM (EST)* **UPDATED ON:** *November 3, 2026, 8:18 AM (EST)*

MERGERSCORP

Fully Licensed Colombian EU Export Cultivation & Processing Hub

Fully licensed, export-ready Colombian cultivation and processing platform with GACP certification, EU-GMP Part I approval, and established EU distribution access. Proven export execution with ~1 tonne already shipped into European medical markets; includes advanced processing infrastructure and PLC 2500 purification system.

TARGET PRICE
$7,000,000

GROSS REVENUE
$12,500,000

EBITDA
$6,000,000

REVENUE MULTIPLE
0.56x

EBITDA MULTIPLE
1.17x

BUSINESS TYPE
Manufacturing

COUNTRY
Colombia

BUSINESS ID
L#20261067

Unbeatable Production Arbitrage

- **Ultra-Low Costs:** All-in production costs of €0.30 per gram, with further downward pressure expected as the facility scales toward its 25+ tonne licensed capacity.
- **Elite Genetics:** Proven high-THC cultivars (mid-20% THC) featuring advanced terpene profiles tailored for European and Australian markets.
- **Ideal Climate:** Located in a premium microclimate with stable, predictable conditions enabling year-round cultivation.

Institutional-Grade Infrastructure & Scalability

- **Immediate Capacity:** 1.7 hectares of interconnected greenhouses currently producing 5.7 tonnes of dried flower annually.
- **Expansion Ready:** Fully licensed 15-hectare site with capacity for 25+ tonnes, enabling significant scale-up with minimal additional capex.
- **Operational Autonomy:** Dedicated on-site power substation with diesel backup and a 20,000 m³ rainwater reservoir supported by a sophisticated water treatment system.

Advanced Post-Harvest & Processing Technology

- **Dual-Track Facility:** Separate buildings for GACP post-harvest and EU-GMP / TGA GMP-compliant processing.
- **Unique Technology Edge:** Includes Colombia's only PLC 2500 purification system and an X-ray sterilization unit required for the Australian market.
- **On-Site Laboratory:** Fully equipped lab enabling real-time potency and purity testing to ensure pharmaceutical-grade standards.

Validated Global Export Track Record

- **Proven Market Access:** One of the few Colombian producers with established exports; approximately 1 tonne already delivered to European markets.
- **De-Risked Revenue:** Sale includes a binding 3-year offtake agreement and established distribution relationships in Germany and the UK.

Turnkey Transition & Strategic Value

- **Investment Value:** Over USD $12M already invested in infrastructure, licensing, and elite genetics.
- **Financial Status:** Debt-free; all related-party debt is forgiven at closing.
- **Shortcut to Market:** Bypasses the typical 3-year development cycle including site selection, construction, and regulatory approvals in Colombia.

MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC. A US CORPORATION WITH REGISTERED OFFICE AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA.

- **Management Continuity:** Core leadership team, including production specialists, will remain to ensure a seamless operational transition.
- **Tax Efficiency:** Tax loss carryforwards (~USD $1.5M) available through 2036, preserved under the share sale structure.

Financial Forecast

Parameter / Metric	Conservative Scenario	Base Scenario	Optimistic Scenario
Asking / Target Price	TBD (On Request)	TBD (On Request)	TBD (On Request)
Annual Finished Extraction Capacity	~5,000 kg	~8,000 kg	~12,000 kg
Average Export Price / Gram (EU GMP)	$2.50 / g	$3.50 / g	$4.50 / g
Estimated Gross Revenue	**~$12,500,000 USD**	**~$28,000,000 USD**	**~$54,000,000 USD**
Estimated Production & OPEX	~$6,500,000 USD	~$12,000,000 USD	~$21,000,000 USD
Estimated EBITDA	**~$6,000,000 USD**	**~$16,000,000 USD**	**~$33,000,000 USD**
EBITDA Margin	**~48%**	**~57%**	**~61%**

MERGERSCORP M&A INTERNATIONAL IS A GLOBAL BRAND OPERATED BY MERGERSUS INC. A US CORPORATION WITH REGISTERED OFFICE AT 40TH WALL STREET, SUITE #2725, NEW YORK, NEW YORK 10005, UNITED STATES OF AMERICA.

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website https://www.mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM